AGENUS INC Form 8-K

March 05, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT Pursuant to Section 13 or 15(d) of** 

the Securities Exchange Act of 1934

March 5, 2014

Date of Report (Date of earliest event reported)

#### **AGENUS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE** 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

3 Forbes Road

Lexington, MA 02421

(Zip

(Address of principal executive offices) Code)

781-674-4400

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item Results of Operations and Financial Condition 2.02

On March 5, 2014, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2013. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

# Item Other Events 8.01

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 antagonist—target cell-surface checkpoint proteins that control immune responses. The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.2 to this current report on Form 8-K.

#### **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

The following exhibit is furnished herewith:

- 99.1 Fourth Quarter and Full Year 2013 Press Release dated March 5, 2014
- 99.2 Checkpoint Modulator Press Release dated March 5, 2014

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **AGENUS INC.**

Date: March 5, 2014 By: /s/ Garo H. Armen

Garo H. Armen

Chief Executive Officer

## EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Fourth Quarter and Full Year 2013 Press Release dated March 5, 2014
99.2	Checkpoint Modulator Press Release dated March 5, 2014